Switching from zoledronic acid to denosumab increases the risk for developing medication-related osteonecrosis of the jaw in patients with bone metastases

Optimizing antiresorptive treatment in patients with bone metastases: time to initiation, switching strategies, and treatment duration

(2019) AnneMarthe Mjelstad et al.   SUPPORTIVE CARE IN CANCER

Management of bone health in solid tumours: From bisphosphonates to a monoclonal antibody

(2019) Roger von Moos et al.   CANCER TREATMENT REVIEWS

Medication-Related Osteonecrosis of the Jaw: MASCC/ISOO/ASCO Clinical Practice Guideline

(2019) Noam Yarom et al.   JOURNAL OF CLINICAL ONCOLOGY

Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study

(2018) Noopur Raje et al.   LANCET ONCOLOGY

Replacing zoledronic acid with denosumab is a risk factor for developing osteonecrosis of the jaw

(2018) Tomoko Higuchi et al.   Oral Surgery Oral Medicine Oral Pathology Oral Radiology

Denosumab Toxicity When Combined With Anti-angiogenic Therapies on Patients With Metastatic Renal Cell Carcinoma: A GETUG Study

(2018) Aline Guillot et al.   Clinical Genitourinary Cancer

A multicenter case registry study on medication-related osteonecrosis of the jaw in patients with advanced cancer

(2017) Morten Schiodt et al.   SUPPORTIVE CARE IN CANCER

Antiresorptive agent-related osteonecrosis of the jaw: Position Paper 2017 of the Japanese Allied Committee on Osteonecrosis of the Jaw

(2016) Toshiyuki Yoneda et al.   JOURNAL OF BONE AND MINERAL METABOLISM

Design and methods for a Scandinavian pharmacovigilance study of osteonecrosis of the jaw and serious infections among cancer patients treated with antiresorptive agents for the prevention of skeletal-related events

(2016) John Acquavella et al.   Clinical Epidemiology

Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer

(2015) Alison T. Stopeck et al.   SUPPORTIVE CARE IN CANCER

Diagnosis and Management of Osteonecrosis of the Jaw: A Systematic Review and International Consensus

(2014) Aliya A Khan et al.   JOURNAL OF BONE AND MINERAL RESEARCH

American Association of Oral and Maxillofacial Surgeons Position Paper on Medication-Related Osteonecrosis of the Jaw—2014 Update

(2014) Salvatore L. Ruggiero et al.   JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY

Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases

(2011) F. Saad et al.   ANNALS OF ONCOLOGY

Randomized, Double-Blind Study of Denosumab Versus Zoledronic Acid in the Treatment of Bone Metastases in Patients With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple Myeloma

(2011) David H. Henry et al.   JOURNAL OF CLINICAL ONCOLOGY

Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study

(2011) Karim Fizazi et al.   LANCET

RANK ligand inhibition in bone metastatic cancer and risk of osteonecrosis of the jaw (ONJ): non bis in idem?

(2011) Tim Van den Wyngaert et al.   SUPPORTIVE CARE IN CANCER

Denosumab Compared With Zoledronic Acid for the Treatment of Bone Metastases in Patients With Advanced Breast Cancer: A Randomized, Double-Blind Study

(2010) Alison T. Stopeck et al.   JOURNAL OF CLINICAL ONCOLOGY